Abstract
Dipeptidyl peptidase 4 (DPP-4) inhibitors are increasingly used these days in management of diabetes. There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP). We report a case of association between linagliptin use and BP and subsequent treatment with rituximab.
Keywords:
contraindications and precautions; dermatology; drug interactions; endocrine system.
© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.
MeSH terms
-
Aged
-
Anti-Bacterial Agents / therapeutic use
-
Clobetasol / therapeutic use
-
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
-
Drug Eruptions / drug therapy
-
Drug Eruptions / pathology*
-
Humans
-
Linagliptin / administration & dosage
-
Linagliptin / adverse effects*
-
Male
-
Minocycline / therapeutic use
-
Pemphigoid, Bullous / chemically induced*
-
Pemphigoid, Bullous / pathology
-
Prednisone / therapeutic use
-
Rituximab / therapeutic use*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Dipeptidyl-Peptidase IV Inhibitors
-
Linagliptin
-
Rituximab
-
Clobetasol
-
Minocycline
-
Prednisone